<DOC>
	<DOCNO>NCT00801177</DOCNO>
	<brief_summary>The purpose study determine IMC-11F8 safe patient , also determine best dose IMC-11F8 give patient .</brief_summary>
	<brief_title>Study IMC-11F8 Patients With Tumors Who Have Not Responded Standard Therapy</brief_title>
	<detailed_description>The purpose study establish safety profile maximum tolerate dose ( MTD ) fully human anti-EGFR monoclonal antibody IMC-11F8 patient solid tumor file standard therapy standard therapy available .</detailed_description>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologicallyconfirmed , EGFRdetectable EGFRundetectable , unidimensionallymeasurable and/or evaluable solid tumor fail standard therapy standard therapy available . Patients tissue available EGFR test undergo biopsy accessible tumor . ECOG performance status score ≤ 2 study entry . Able provide write informed consent . White blood cell ( WBC ) count ≥ 3 x 109/L ; absolute neutrophil count ≥ 1.5 x 109/L ; hemoglobin level &gt; 90 g/L ; platelet count ≥ 100 x 109/L . Adequate hepatic function define : alkaline phosphatase level ≤ 5.0 x ULN bilirubin level ≤ 1.5 x ULN aspartate transaminase ( AST ) alanine transaminase ( ALT ) level ≤ 2.5 x ULN ≤ 5 x ULN patient liver metastasis Adequate renal function define serum creatinine level within normal limit . Use effective contraception procreative potential exists . Life expectancy approximately 3 month opinion opinion investigator . Chemotherapy , radiation , and/or hormonal therapy ( except palliative radiation therapy diseaserelated pain chronic hormonal therapy prostate carcinoma ) within 4 week study entry . Concurrent unstable uncontrolled medical disease ( e.g. , active uncontrolled systemic infection , poorly control hypertension history poor compliance antihypertensive regimen , unstable angina , congestive heart failure , uncontrolled diabetes ) chronic disease , , opinion investigator , could compromise patient study . Newlydiagnosed symptomatic brain metastasis ( patient history brain metastasis must receive definitive surgery radiotherapy , clinically stable , take steroid ; anticonvulsant allow ) . Any concurrent malignancy basal cell carcinoma carcinoma situ cervix . Patients previous malignancy without evidence disease ≥ 3 year allow enter trial . Any condition prevents patient provide informed consent . Pregnancy ( confirm serum beta human chorionic gonadotropin [ ßHCG ] ) breastfeeding . Any investigational agent ( ) device ( ) within 4 week study entry . Prior treatment cetuximab , epidermal growth factor receptor inhibitor , include tyrosine kinase inhibitor , gefitinib erlotinib . Prior treatment monoclonal antibody target receptor EGFR permit ≥ 4 week prior study entry . Any prior therapy target EGFR EGFR pathway . Known history human immunodeficiency virus . Employees investigator study center direct involvement study study direction investigator study center , well family member employee .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>Tumors</keyword>
	<keyword>Antibodies , Monoclonal</keyword>
</DOC>